Hexagon Capital Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$940K Buy
+6,747
New +$945K 0.14% 69
2025
Q2
Sell
-8,852
Closed -$992K 715
2025
Q1
$992K Sell
8,852
-584
-6% -$60.3K 0.19% 56
2024
Q4
$872K Sell
9,436
-97
-1% -$8.73K 0.16% 65
2024
Q3
$799K Sell
9,533
-684
-7% -$52.2K 0.16% 65
2024
Q2
$701K Buy
10,217
+1,506
+17% +$101K 0.15% 70
2024
Q1
$638K Sell
8,711
-746
-8% -$57.4K 0.14% 75
2023
Q4
$766K Sell
9,457
-175
-2% -$13.6K 0.18% 59
2023
Q3
$722K Buy
9,632
+1,218
+14% +$93.7K 0.19% 51
2023
Q2
$648K Sell
8,414
-403
-5% -$32.1K 0.17% 55
2023
Q1
$732K Buy
8,817
+8
+0.1% +$663 0.2% 47
2022
Q4
$756K Sell
8,809
-2,636
-23% -$209K 0.22% 45
2022
Q3
$706K Buy
11,445
+6,119
+115% +$386K 0.21% 53
2022
Q2
$329K Buy
5,326
+1,689
+46% +$105K 0.1% 123
2022
Q1
$216K Buy
3,637
+1,518
+72% +$97K 0.06% 172
2021
Q4
$154K Hold
2,119
0.04% 212
2021
Q3
$148K Hold
2,119
0.04% 194
2021
Q2
$146K Buy
2,119
+200
+10% +$13.4K 0.04% 194
2021
Q1
$124K Buy
1,919
+500
+35% +$32.2K 0.03% 194
2020
Q4
$82K Sell
1,419
-300
-17% -$18.1K 0.02% 215
2020
Q3
$100K Buy
+1,719
New +$119K 0.03% 176

Other funds holding GILD

Hexagon Capital Partners's GILD Position: Q1 2026 in Review

Hexagon Capital Partners opened a new position in Gilead Sciences (GILD) in Q1 2026: 6,747 shares worth $940K. The stake represents 0.14% of the portfolio and ranks #69 among its holdings. This is a return to the name: Hexagon Capital Partners previously reported a position in GILD as recently as Q1 2025.

Hexagon Capital Partners first reported a position in GILD in Q3 2020 and has held it in 20 quarters since. The position peaked at $992K in Q1 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Hexagon Capital Partners held 6,747 shares of Gilead Sciences worth $940K as of Q1 2026.
  • Gilead Sciences was a new Hexagon Capital Partners position in Q1 2026.
  • Gilead Sciences made up 0.14% of Hexagon Capital Partners's portfolio in Q1 2026, its #69 holding.
  • Hexagon Capital Partners first reported a position in Gilead Sciences in Q3 2020 and has held it in 20 quarters since.
  • Hexagon Capital Partners's Gilead Sciences position peaked at $992K in Q1 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Hexagon Capital Partners's 13F filing for Q1 2026, filed 5 May 2026.